4.有關raloxifene於骨鬆症治療之敘述,下列何者錯誤?
(A)須考量靜脈栓塞病史
(B)依creatinine clearance調整劑量
(C)須注意與cholestyramine之交互作用
(D)須考量肺栓塞之風險
答案:登入後查看
統計: A(63), B(1791), C(316), D(377), E(0) #3197702
統計: A(63), B(1791), C(316), D(377), E(0) #3197702
詳解 (共 9 筆)
#6160889
57.下列何項藥品與L-thyroxine口服併用時,應間隔至少12小時?
(A) iron
(B) calcium
(C) raloxifene
(D) estrogen
ㅤㅤ
答案:C
32
2
#6028628
(A) 須考量靜脈栓塞病史
(B) 無須依creatinine clearance調整劑量
(C) 須注意與cholestyramine之交互作用
(D) 須考量肺栓塞之風險
ㅤㅤ
[US Boxed Warning]: Raloxifene may increase the risk for deep vein thrombosis and pulmonary embolism (A)(D); use is contraindicated in patients with history of or current venous thromboembolic disorders
Ref. UptoDate
Dosing: Kidney Impairment: Adult
CrCl ≤50 mL/minute: There are no dosage adjustments (B) provided in the manufacturer’s labeling; use with caution.
Ref. UptoDate
Concurrent use of CHOLESTYRAMINE and RALOXIFENE may result in reduced raloxifene absorption and clinical efficacy (D).
Ref. Micromedex
23
4